Novo Nordisk says FDA rejects insulin drugs - WDRB 41 Louisville News

Novo Nordisk says FDA rejects insulin drugs

Posted: Updated:

NEW YORK (AP) -- Novo Nordisk AS says the Food and Drug Administration rejected its applications for approval of once-per-day insulin drugs to treat diabetes.

The Danish drugmaker says it received a "complete response letter" from the FDA regarding its applications for approval of Tresiba and Ryzodeg, or insulin degludec, on Friday. Such a letter indicates the agency determined the application cannot be approved in its current form.

In November, panel of federal health advisers recommended that the government approve degludec. The FDA is not required to follow the group's advice, but it often does.

Tresiba contains long-acting insulin, and Ryzodeg contains both long- and short-acting insulins.

Diabetics either do not produce enough of the hormone insulin or do not use it efficiently, allowing excess sugar, or glucose, to accumulate in the blood.

  • Closed CaptioningMore>>

  • Closed Captioning Message

    Thanks to a grant from Norton Healthcare, this story and others are available in real-time closed captioning on WDRB.
    Thanks to a grant from Norton Healthcare, this story and others are available in real-time closed captioning on WDRB.More >>
Powered by WorldNow
All content © Copyright 2000 - 2014 WorldNow and WDRB. All Rights Reserved. For more information on this site, please read our Privacy Policy and Terms of Service.